The note states AUBANK reported 7.0% QoQ gross advances growth and 28.6% YoY deposit growth, and calls it its top pick among mid-sized private banks with 29% upside from CMP INR987.
Read this note →Research notes
What India's research desks published, reported with attribution and linked to the original notes. Orivam issues no recommendations of its own.
2554 notes · all time
The note says RBI approval of Anup Bagchi as MD & CEO from 27 Oct'26 removes a key leadership-succession overhang.
Read this note →The note says Bajaj Finance's 2QFY27 AUM of INR5.85t (up ~26.5% YoY) was higher than its estimates with customer franchise at ~128.85m.
Read this note →The note says DMart's 2QFY27 standalone revenue of INR192b grew 18.4% YoY, slightly ahead of its last published estimate.
Read this note →The note says Accenture's 4QFY26 revenue of USD18.7b (up 7% YoY cc) beat guidance but shows no sequential change in discretionary spending, so it does not alter the firm's cautious 2QFY27 outlook for Indian IT services.
Read this note →The note says Canon is in discussions with players in major Indian semiconductor projects and is setting up local service centres.
Read this note →The note says NetApp named India its fastest-growing Asian market on enterprise cloud adoption and BFSI/IT demand.
Read this note →The note says IBM India highlighted rising demand for secure, governed AI systems and infrastructure as Indian firms raise AI spending.
Read this note →The note cites a forecast of 3.5% sequential growth for Mphasis in Q2 FY27.
Read this note →The note cites a forecast of 4.5% sequential growth for Coforge in Q2 FY27, aided by large deal wins and acquisitions.
Read this note →The note reports mid-tier IT firms are expected to outperform larger peers in Q2 FY27, with Persistent forecast to grow 7% sequentially.
Read this note →The note says Jio Platforms is preparing to list by late October with a record $3.8 billion IPO at an enterprise valuation above Rs 12 trillion.
Read this note →The note says the B2B commerce platform plans to file its DRHP in November and launch an IPO next year to raise roughly $1 billion.
Read this note →The note says ESDS Software Solutions led H1 FY27 IPO gains with a 233.7% return.
Read this note →The report initiates coverage on Molbio Diagnostics with a BUY rating and a 12-month target price of INR1,800, implying about 19-21% upside, based on a 45x 12-month forward P/E (a 20% premium to the sector multiple of 36x), citing its differentiated R&D-driven business model and expected 23% revenue CAGR and 50% PAT CAGR over FY26-29E, while flagging customer concentration, high TB revenue dependence, regulatory delays and working-capital intensity as key risks.
Read this note →The report reiterates a BUY rating with a target price of Rs 1,225, stating that the appointment of Anup Bagchi as MD & CEO removes leadership overhang and should help restore investor and customer confidence, with re-rating expected as business execution improves and FPI outflows moderate.
Read this note →The report says it received Mainboard approval for a fresh issue of 57.62 lakh shares and an OFS of 15.15 lakh shares.
Read this note →The report says it received Mainboard approval for a fresh issue of 1.187 crore shares and an OFS of 0.728 crore shares.
Read this note →The report says it received Mainboard approval with issue details marked confidential.
Read this note →The report says it received Mainboard DRHP approval for a ₹550 crore fresh issue.
Read this note →The report says it proposed an ₹800 crore fresh issue along with OFS of ₹200 crore.
Read this note →The report says it proposed a ₹550 crore fresh issue along with OFS of ₹450 crore.
Read this note →The report says it proposed a ₹525 crore fresh issue cum OFS of ₹200 crore.
Read this note →The report says it proposed a ₹500 crore fresh issue cum OFS of 0.15 crore shares.
Read this note →The report says it filed a Mainboard DRHP with a ₹600 crore fresh issue and up to 1 crore shares as promoter OFS.
Read this note →